Effects of Eicosapentaenoic Acid Supplementation in the Treatment of Chronic Hepatitis C Patients

Tomioka, Kayoko; Kakibuchi, Naoko; Murakami, Yasuko; Kawakami, Takayo; Takaguchi, Kouichi; Kita, Keiji; Okita, Misako

doi:10.3177/jnsv.51.419

Cited by 8 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the lymphocyte count in the EPA group did not decrease compared with the basal level, but the leukocyte count decreased significantly in both groups after 4 weeks of therapy. These results are similar to those in our previous study [22], in which EPA supplementation for 24 weeks in chronic hepatitis C patients receiving combination therapy of IFN a-2b and ribavirin prevented decreases in leukocyte and lymphocyte counts. It was reported that the side effects caused by PEG-IFN a-2b/ribavirin combination therapy were more serious compared with those caused by IFN a-2b because PEG-IFN a-2b is a conjugated protein and its metabolism and excretion are prolonged [15,25,26].…”

Section: Discussionsupporting

confidence: 91%

“…EPA supplementation in patients with chronic hepatitis C is reported to improve ribavirin-related anemia [20], and it was suggested that the increased EPA level in erythrocyte membranes may be associated with increased membrane fluidity and viscoelastic properties of erythrocyte membranes [21]. We also reported that EPA supplementation improved the serum ALT level and prevented a decrease in lymphocyte counts, which were significantly decreased from the baseline during the treatment in non-EPA supplemented patients receiving combination therapy of IFN a-2b and ribavirin, and suggested the usefulness of EPA supplementation for the treatment of HCV-infected patients [22]. However, longer and more detailed research is required to confirm its efficacy.…”

Section: Introductionmentioning

confidence: 60%

See 1 more Smart Citation

Eicosapentaenoic Acid Supplementation for Chronic Hepatitis C Patients During Combination Therapy of Pegylated Interferon α‐2b and Ribavirin

Kawashima

Tsukamoto

Koyabu

et al. 2008

Lipids

Self Cite

View full text Add to dashboard Cite

Eicosapentaenoic acid (EPA) (1.8 g/day) was administered to 12 chronic hepatitis C patients receiving combination therapy of pegylated interferon (PEG-IFN) alpha-2b and ribavirin for 48 weeks (EPA group). Twelve patients were not administered EPA (control group). All patients also received vitamin E and C (300, 600 mg/day, respectively) during the therapy. Serum alanine aminotransferase improved to a normal level in 8 of 12 patients from the EPA group and 6 of 12 patients from the control group after 12 weeks. Lymphocyte counts decreased significantly after 8 weeks in the control group, but not the EPA group. T-helper (Th) 1 decreased after 4 weeks in the control group, but not in the EPA group (two-way ANOVA; P < 0.05). Th1/Th2 ratios were elevated in 9 of 12 patients in the EPA group, and 3 out of 12 in the control group (P < 0.05) after 8 weeks. After 12 weeks, the arachidonic acid/EPA molar ratio of erythrocyte membrane phospholipid correlated negatively with the leukocyte count (n = 24, r = -0.439, P < 0.05) and the neutrophil count (n = 24, r = -0.671, P < 0.02). The hemoglobin level improved after 48 weeks compared with 24 weeks in only the EPA group. These findings suggest that EPA supplementation may be useful in therapy for chronic hepatitis C.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 60%

Eicosapentaenoic Acid Supplementation for Chronic Hepatitis C Patients During Combination Therapy of Pegylated Interferon α‐2b and Ribavirin

Kawashima

Tsukamoto

Koyabu

et al. 2008

Lipids

Self Cite

View full text Add to dashboard Cite

show abstract

“…A reduced dietary antioxidant intake associated with a lack of appetite may decrease the antioxidant capacity of patients. In our previous studies, vitamin E and C supplementation during IFN ␣ -2b plus ribavirin therapy prevented a decrease in the eicosapentaenoic acid (EPA) level of mononuclear cell phospholipids ( 10 ), and EPA supplementation with vitamins E and C prevented a decrease in the lymphocyte counts during IFN ␣ -2b plus ribavirin therapy ( 11 ). Reduced levels of plasma ␣tocopherol and ascorbic acid in hepatitis C patients were also observed ( 10 ).…”

mentioning

confidence: 89%

Zinc Supplementation Prevents the Increase of Transaminase in Chronic Hepatitis C Patients during Combination Therapy with Pegylated Interferon .ALPHA.-2b and Ribavirin

Murakami

Koyabu

Kawashima

et al. 2007

J Nutr Sci Vitaminol

Self Cite

View full text Add to dashboard Cite

We investigated the effects of zinc supplementation on clinical observations in chronic hepatitis C patients receiving pegylated interferon (PEG-IFN) ␣-2b plus ribavirin combination therapy. Patients were randomly allocated to receive 150 mg polaprezinc (zinc group, n ϭ 11) or no supplement (control group, n ϭ 12) daily in addition to PEG-IFN ␣-2b plus ribavirin therapy and 300 mg vitamin E and 600 mg vitamin C supplementation daily for 48 wk. Among the patients who continued treatment, the serum alanine aminotransferase (ALT) level at 12 wk in the zinc group was significantly lower than that in the control group. All patients in the zinc group (9/9) and 67% (8/12) of the control patients at 24 wk, and all patients in the zinc group (7/7) and 60% (6/10) of the control patients at 48 wk showed a decrease in serum ALT levels to within the normal range (7-44 U/L). HCV RNA disappeared in all patients (7/7) in the zinc group and in 8 of 10 control patients at 48 wk. Polaprezinc supplementation decreased plasma thiobarbituric acid reactive substances and prevented the decrease of polyunsaturated fatty acids of erythrocyte membrane phospholipids. No significant differences were observed in the dosage of medicines or other clinical data during the treatment. These observations indicate that polaprezinc supplementation may have induced some antioxidative functions in the liver which resulted in reduced hepatocyte injury during PEG-IFN ␣-2b plus ribavirin therapy.

show abstract

“…These patients had clearly lower plasma and serum 8-oxo-dG levels after six-months of treatment with IFN-a, ribavirin, and antioxidants (300 mg a-tocopherol/day and 600 mg ascorbic acid/day). EPA supplementation also decreased the ratio of AA to EPA and increased leukocyte levels (Tomioka et al, 2005;Kawashima et al, 2008); suggesting treatment with EPA prevents AA accumulation. Thus, these observations suggest that the combination of EPA and antioxidants (vitamin C and vitamin E) may ameliorate inflammation and oxidative stress and thereby increase the response of antiviral therapy in HCV-infected patients.…”

Section: Vitamin C E and Eicosapentaeoic Acid Supplementationmentioning

confidence: 94%

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C

Guo¹,

Chen²

2012

Antioxidant Enzyme

View full text Add to dashboard Cite

Effects of Eicosapentaenoic Acid Supplementation in the Treatment of Chronic Hepatitis C Patients

Cited by 8 publications

References 30 publications

Eicosapentaenoic Acid Supplementation for Chronic Hepatitis C Patients During Combination Therapy of Pegylated Interferon α‐2b and Ribavirin

Eicosapentaenoic Acid Supplementation for Chronic Hepatitis C Patients During Combination Therapy of Pegylated Interferon α‐2b and Ribavirin

Zinc Supplementation Prevents the Increase of Transaminase in Chronic Hepatitis C Patients during Combination Therapy with Pegylated Interferon .ALPHA.-2b and Ribavirin

Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C

Contact Info

Product

Resources

About